Temozolomide in combination with other cytotoxic agents

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 13, 2001, Pages 24-33

  Prados, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; NITROSOUREA DERIVATIVE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SAFETY; HUMAN; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0034822982     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.2651     Document Type: Review

References (22)

1. Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea
2. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide
3. O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L 1210 leukemia
4. Protracted daily administration of temozolomide is feasible: A phase I and pharmacokinetic/pharmacodynamic study
5. Protracted cyclic administration of temozolomide is feasible: A phase I, pharmacokinetic and pharmacodynamic study
6. Persistent and marked inactivation of O-6-alkylguanine-DNA alkyltransferase (AGAT), a mechanism of resistance to alkylators, with protracted low-dose oral schedules of temozolomide
7. 6benzylguanine in brain tumor models
8. 6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea
9. A phase I trial of 1,3 bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium study
10. A phase I and pharmacokinetic (PK) trial of 2 sequences of BCNU and temozolomide (TMZ) in patients with advanced solid tumors
11. A phase II study of BCNU and temozolomide for recurrent glioblastoma multiforme: A North American Brain Tumor Consortium study
12. Phase I trials of Gliadel plus CPT-11 or Temodar
13. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse
14. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN- 38
15. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models
16. Anticonvulsants alter the pharmacokinetics of irinotecan (CPT-11) in patients with recurrent glioma
17. Irinotecan therapy in adults with recurrent or progressive malignant glioma
18. A phase I (intrapatient dose escalation) open-label study of irinotecan (CPT-11) in patients with recurrent or progressive malignant glioma
19. A phase 11 trial of irinotecan (CPT-11) in recurrent glioma
20. A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Consortium (NABTC) study
21. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies